Literature DB >> 18577869

Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma.

R A Smith1, L Bosonnet, P Ghaneh, M Raraty, R Sutton, F Campbell, J P Neoptolemos.   

Abstract

BACKGROUND: The aim of this study was to identify whether preoperative CA19-9 levels might represent an independent prognostic marker for overall survival in patients undergoing resection for pancreatic ductal adenocarcinoma, and to describe the relationship between CA19-9 and tumour histology.
METHODS: 109 patients who had a pancreatoduodenectomy for pancreatic ductal adenocarcinoma with recorded preoperative CA19-9 levels were identified from a prospectively maintained database (1997-2006). Multivariate analysis was conducted using a Cox proportional hazards model with continuous covariates where possible.
RESULTS: The median survival of 64 patients with a preoperative CA19-9 level >150 kU/l was 10.4 months while in 45 patients with a CA19-9 level <or=150 kU/l this was 22.1 months (corrected p = 0.012). Also significant on univariate analyses were overall lymph node status (p = 0.011), lymph node ratio (p = 0.003) and tumour diameter (p = 0.004). Preoperative CA19-9 levels >150 kU/l were associated with a larger, more poorly differentiated tumour along with an increased likelihood of a positive resection margin status (all p < 0.05). Preoperative CA19-9 levels (p = 0.030) and lymph node ratio (p = 0.042) emerged as independent predictors of survival on multivariate analysis.
CONCLUSIONS: Preoperative CA19-9 levels and lymph node ratio were significant predictors of survival in resected pancreatic ductal adenocarcinoma. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577869     DOI: 10.1159/000140961

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  28 in total

1.  Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.

Authors:  Ludmila Katherine Martin; Lai Wei; Elizabeth Trolli; Tanios Bekaii-Saab
Journal:  Med Oncol       Date:  2012-06-24       Impact factor: 3.064

2.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

3.  Lymph node retrieval in pancreaticoduodenectomy specimens: does educating the pathologist matter?

Authors:  D Rohan Jeyarajah; Amit Khithani; Veeraiah Siripurapu; Elizabeth Liu; Ashley Thomas; A Joe Saad
Journal:  HPB (Oxford)       Date:  2013-05-15       Impact factor: 3.647

4.  Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute.

Authors:  Yajie Zhao; Chengfeng Wang
Journal:  J Gastrointest Surg       Date:  2019-04-03       Impact factor: 3.452

5.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases.

Authors:  Humaid O Al-Shamsi; Mohammed Alzahrani; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-06

Review 7.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

8.  Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma.

Authors:  Sabrina C Wentz; Zhi-Guo Zhao; Yu Shyr; Chan-Juan Shi; Nipun B Merchant; Kay Washington; Fen Xia; A Bapsi Chakravarthy
Journal:  World J Gastrointest Oncol       Date:  2012-10-15

9.  Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?

Authors:  Ioannis T Konstantinidis; Vikram Deshpande; Hui Zheng; Jennifer A Wargo; Carlos Fernandez-del Castillo; Sarah P Thayer; Vasiliki Androutsopoulos; Gregory Y Lauwers; Andrew L Warshaw; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

10.  Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

Authors:  C Dive; R A Smith; E Garner; T Ward; S St George-Smith; F Campbell; W Greenhalf; P Ghaneh; J P Neoptolemos
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.